# Safety and Patient Satisfaction With GLASH VISTA™ (Bimatoprost 0.03%) in the Treatment of Eyelash Hypotrichosis in Japan

> **NCT02505776** · — · COMPLETED · sponsor: **Allergan** · enrollment: 1699 (actual)

## Conditions studied

- Eyelash Hypotrichosis

## Interventions

- **DRUG:** Bimatoprost cutaneous solution 0.03%

## Key facts

- **NCT ID:** NCT02505776
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-08
- **Primary completion:** 2018-05-21
- **Final completion:** 2018-05-21
- **Target enrollment:** 1699 (ACTUAL)
- **Last updated:** 2018-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02505776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02505776, "Safety and Patient Satisfaction With GLASH VISTA™ (Bimatoprost 0.03%) in the Treatment of Eyelash Hypotrichosis in Japan". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02505776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*